A relapszus-remisszió kórformájú sclerosis multiplexes betegek kezelése interferon-béta-1b-vel.

Translated title of the contribution: Treatment of relapsing-remitting multiple sclerosis with interferon beta type 1-b

K. Bencsik, C. Rajda, P. Klivényi, T. Járdánházy, M. Török, L. Vécsei

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Interferon-beta-1b was the first drug found to slow the progression of relapsing-remitting multiple sclerosis, with a reported decrease in the relapse rate of up to 34%. The present study involved 35 patients treated with interferon-beta-1b for one year. The aims of the study were: a) to compare the changes in the relapse rate and the number of days of hospitalization with other data, b) to compare the steroid needs required to treat relapses for one year before and in the year of interferon-beta-1b treatment. Our data indicated that the relapse rate may decrease as much as 77% following the introduction of interferon-beta-1b treatment. The adverse effects and the changes in the EDSS grades were similar to the published data. The duration of hospitalization decreased by 84% and the amount of methylprednisolone needed for remission by 78%. This data suggest that the impairment of the condition of the patients may be delayed considerably, while some of them can continue to work for a longer period, the standard of life of these patients therefore being more tolerable.

Original languageHungarian
Pages (from-to)763-766
Number of pages4
JournalOrvosi Hetilap
Volume140
Issue number14
Publication statusPublished - Apr 4 1999

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Interferon Type I
Recurrence
Hospitalization
Methylprednisolone
Therapeutics
Steroids
Interferon beta-1b
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A relapszus-remisszió kórformájú sclerosis multiplexes betegek kezelése interferon-béta-1b-vel. / Bencsik, K.; Rajda, C.; Klivényi, P.; Járdánházy, T.; Török, M.; Vécsei, L.

In: Orvosi Hetilap, Vol. 140, No. 14, 04.04.1999, p. 763-766.

Research output: Contribution to journalArticle

@article{3f3713cee7034744b8ffc59ed56ab530,
title = "A relapszus-remisszi{\'o} k{\'o}rform{\'a}j{\'u} sclerosis multiplexes betegek kezel{\'e}se interferon-b{\'e}ta-1b-vel.",
abstract = "Interferon-beta-1b was the first drug found to slow the progression of relapsing-remitting multiple sclerosis, with a reported decrease in the relapse rate of up to 34{\%}. The present study involved 35 patients treated with interferon-beta-1b for one year. The aims of the study were: a) to compare the changes in the relapse rate and the number of days of hospitalization with other data, b) to compare the steroid needs required to treat relapses for one year before and in the year of interferon-beta-1b treatment. Our data indicated that the relapse rate may decrease as much as 77{\%} following the introduction of interferon-beta-1b treatment. The adverse effects and the changes in the EDSS grades were similar to the published data. The duration of hospitalization decreased by 84{\%} and the amount of methylprednisolone needed for remission by 78{\%}. This data suggest that the impairment of the condition of the patients may be delayed considerably, while some of them can continue to work for a longer period, the standard of life of these patients therefore being more tolerable.",
author = "K. Bencsik and C. Rajda and P. Kliv{\'e}nyi and T. J{\'a}rd{\'a}nh{\'a}zy and M. T{\"o}r{\"o}k and L. V{\'e}csei",
year = "1999",
month = "4",
day = "4",
language = "Hungarian",
volume = "140",
pages = "763--766",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "14",

}

TY - JOUR

T1 - A relapszus-remisszió kórformájú sclerosis multiplexes betegek kezelése interferon-béta-1b-vel.

AU - Bencsik, K.

AU - Rajda, C.

AU - Klivényi, P.

AU - Járdánházy, T.

AU - Török, M.

AU - Vécsei, L.

PY - 1999/4/4

Y1 - 1999/4/4

N2 - Interferon-beta-1b was the first drug found to slow the progression of relapsing-remitting multiple sclerosis, with a reported decrease in the relapse rate of up to 34%. The present study involved 35 patients treated with interferon-beta-1b for one year. The aims of the study were: a) to compare the changes in the relapse rate and the number of days of hospitalization with other data, b) to compare the steroid needs required to treat relapses for one year before and in the year of interferon-beta-1b treatment. Our data indicated that the relapse rate may decrease as much as 77% following the introduction of interferon-beta-1b treatment. The adverse effects and the changes in the EDSS grades were similar to the published data. The duration of hospitalization decreased by 84% and the amount of methylprednisolone needed for remission by 78%. This data suggest that the impairment of the condition of the patients may be delayed considerably, while some of them can continue to work for a longer period, the standard of life of these patients therefore being more tolerable.

AB - Interferon-beta-1b was the first drug found to slow the progression of relapsing-remitting multiple sclerosis, with a reported decrease in the relapse rate of up to 34%. The present study involved 35 patients treated with interferon-beta-1b for one year. The aims of the study were: a) to compare the changes in the relapse rate and the number of days of hospitalization with other data, b) to compare the steroid needs required to treat relapses for one year before and in the year of interferon-beta-1b treatment. Our data indicated that the relapse rate may decrease as much as 77% following the introduction of interferon-beta-1b treatment. The adverse effects and the changes in the EDSS grades were similar to the published data. The duration of hospitalization decreased by 84% and the amount of methylprednisolone needed for remission by 78%. This data suggest that the impairment of the condition of the patients may be delayed considerably, while some of them can continue to work for a longer period, the standard of life of these patients therefore being more tolerable.

UR - http://www.scopus.com/inward/record.url?scp=0033522249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033522249&partnerID=8YFLogxK

M3 - Article

C2 - 10224846

AN - SCOPUS:0033522249

VL - 140

SP - 763

EP - 766

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 14

ER -